OncoMatch

OncoMatch/Clinical Trials/NCT06942104

Imaging of Solid Tumors Using 18F-TRX

Is NCT06942104 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies 18F-TRX for solid tumor.

Phase 1RecruitingRahul AggarwalNCT06942104Data as of May 2026

Treatment: 18F-TRXThis phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan. It specifically targets and detects labile (unstable) iron levels within tissues, including tumors. Diagnostic procedures, such as 18F-TRX PET/CT or PET/MRI, may help detect tumors in patients with solid tumors

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Prostate Cancer

Renal Cell Carcinoma

Glioblastoma

Disease stage

Required: Stage III, IV, STAGE III RENAL CELL CANCER AJCC V8, STAGE IV RENAL CELL CANCER AJCC V8, STAGE IVB PROSTATE CANCER AJCC V8 (AJCC v8)

Grade: WHO grade 3WHO grade 4 (WHO)

Advanced solid tumor malignancy in one of the following cohorts: ... WHO grade 3 or 4 glioma ... Locally advanced or metastatic clear cell renal cell carcinoma ... Metastatic castration-resistant prostate cancer ... Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

Absolute neutrophil count > 1.5 x 10^6/L; Platelets > 75,000 x 10^6/L; Hemoglobin > 8 g/dL

Kidney function

Creatinine clearance > 50 ml/min, calculated using the Cockcroft-Gault equation

Liver function

Total bilirubin < 1.5 x upper limit of normal; AST < 2.5 x ULN (< 5 x ULN with liver metastases); ALT < 2.5 x ULN (< 5 x ULN with liver metastases)

Absolute neutrophil count > 1.5 x 10^6/L; Platelets > 75,000 x 10^6/L; Hemoglobin > 8 g/dL; Total bilirubin < 1.5 x upper limit of normal; AST < 2.5 x ULN (< 5 x ULN with liver metastases); ALT < 2.5 x ULN (< 5 x ULN with liver metastases); Creatinine clearance > 50 ml/min, calculated using the Cockcroft-Gault equation.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of California, San Francisco · San Francisco, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify